452 related items for PubMed ID: 17424707
1.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
2.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
3.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
4.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
5. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[Abstract] [Full Text] [Related]
6. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.
Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
[Abstract] [Full Text] [Related]
7.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
8. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A.
Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):513-20. PubMed ID: 20137862
[Abstract] [Full Text] [Related]
9. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
Oncol Rep; 2005 Oct 01; 14(4):933-40. PubMed ID: 16142354
[Abstract] [Full Text] [Related]
10.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
12. Intensive therapy and autotransplantation in Hodgkin's disease.
Reece DE, Phillips GL.
Stem Cells; 1994 Sep 01; 12(5):477-93. PubMed ID: 7804123
[Abstract] [Full Text] [Related]
13. Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Sperotto A, Damiani D, Zaja F, Patriarca F, Geromin A, Cerno M, Stocchi R, Tiribelli M, Skert C, Rinaldi C, Fanin R.
Adv Clin Path; 2002 Apr 01; 6(2):77-85. PubMed ID: 19753729
[Abstract] [Full Text] [Related]
14.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
15. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
Bone Marrow Transplant; 2000 Aug 01; 26(4):383-8. PubMed ID: 10982284
[Abstract] [Full Text] [Related]
16. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK, Wittekind C, Niederwieser D.
Dtsch Med Wochenschr; 2007 Aug 01; 132(33):1688-91. PubMed ID: 17713864
[Abstract] [Full Text] [Related]
17. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY, Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou AP, Feng FY.
Ai Zheng; 2002 Apr 01; 21(4):405-8. PubMed ID: 12452021
[Abstract] [Full Text] [Related]
18. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T.
Bone Marrow Transplant; 2008 Apr 01; 41(7):613-9. PubMed ID: 18071290
[Abstract] [Full Text] [Related]
19. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J.
Biol Blood Marrow Transplant; 1997 Jun 01; 3(2):98-106. PubMed ID: 9267670
[Abstract] [Full Text] [Related]
20.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
Page: [Next] [New Search]
